{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:34:02Z","timestamp":1790724842953,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clml.2020.09.010","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T11:49:03Z","timestamp":1601552943000},"page":"e152-e159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira S.","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-7626","authenticated-orcid":false,"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.09.010_bib1","unstructured":"National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed: May 14, 2020."},{"key":"10.1016\/j.clml.2020.09.010_bib2","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.09.010_bib3","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1634\/theoncologist.2011-0252","article-title":"Patient-centered cancer treatment planning: improving the quality of oncology care. Summary of an Institute of Medicine workshop","volume":"16","author":"Balogh","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.09.010_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","article-title":"Health care costs and resource utilization, including patient burden, associated with novel-agent\u2013based treatment versus other therapies for multiple myeloma: findings using real-world claims data","volume":"18","author":"Teitelbaum","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.09.010_bib5","first-page":"818","article-title":"Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone","volume":"22","author":"Hagiwara","year":"2019","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clml.2020.09.010_bib6","first-page":"793","article-title":"Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed\/refractory multiple myeloma","volume":"21","author":"Hari","year":"2018","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clml.2020.09.010_bib7","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.2217\/fon-2019-0422","article-title":"Lenalidomide maintenance post-transplantation in newly diagnosed multiple myeloma: real-world outcomes and costs","volume":"15","author":"Hari","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2020.09.010_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamacardio.2015.0248","article-title":"Moving from disease-centered to patient goals-directed care for patients with multiple chronic conditions: patient value-based care","volume":"1","author":"Tinetti","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clml.2020.09.010_bib9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/1472-6963-14-281","article-title":"Rethinking the patient: using burden of treatment theory to understand the changing dynamics of illness","volume":"14","author":"May","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clml.2020.09.010_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PROM.S34681","article-title":"Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study","volume":"3","author":"Eton","year":"2012","journal-title":"Patient Relat Outcome Meas"},{"key":"10.1016\/j.clml.2020.09.010_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1525-1497.2005.0117.x","article-title":"Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens","volume":"20","author":"Vijan","year":"2005","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.clml.2020.09.010_bib12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1741-7015-10-68","article-title":"Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions","volume":"10","author":"Tran","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.clml.2020.09.010_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1477-7525-7-83","article-title":"Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device)","volume":"7","author":"Brod","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clml.2020.09.010_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/jgs.15715","article-title":"Geriatric assessment in older adults with multiple myeloma","volume":"67","author":"Wildes","year":"2019","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.clml.2020.09.010_bib15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1049909116646337","article-title":"Self-reported quality of life and symptom burden in ambulatory patients with multiple myeloma on disease-modifying treatment","volume":"34","author":"Kiely","year":"2017","journal-title":"Am J Hospice Palliat Med"},{"key":"10.1016\/j.clml.2020.09.010_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2020.09.010_bib17","first-page":"978391","article-title":"Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare","volume":"2012","author":"Griffiths","year":"2012","journal-title":"J\u00a0Cancer Epidemiol"},{"key":"10.1016\/j.clml.2020.09.010_bib18","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2020.09.010_bib19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2020.09.010_bib20","article-title":"Development of an algorithm to distinguish smoldering versus symptomatic multiple myeloma in claims-based data sets","volume":"1","author":"Fiala","year":"2017","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clml.2020.09.010_bib21","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1200\/JOP.2016.014100","article-title":"Treatment burden of Medicare beneficiaries with stage I non\u2013small-cell lung cancer","volume":"13","author":"Presley","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clml.2020.09.010_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2803","article-title":"We need minimally disruptive medicine","volume":"339","author":"May","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2020.09.010_bib23","first-page":"1","article-title":"Measures of treatment workload for patients with breast cancer","volume":"3","author":"Cheng","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clml.2020.09.010_bib24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jgo.2018.05.015","article-title":"Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant","volume":"10","author":"Rosko","year":"2019","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.clml.2020.09.010_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/10428194.2019.1648802","article-title":"Burden of disease progression in patients with multiple myeloma in the US","volume":"61","author":"Hagiwara","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.09.010_bib26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.09.010_bib27","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.09.010_bib28","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2020.09.010_bib29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/ejh.13044","article-title":"Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: results from a prospective, multinational, observational study","volume":"100","author":"Ashcroft","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.09.010_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1634\/theoncologist.2009-0290","article-title":"Polypharmacy in older adults with cancer","volume":"15","author":"Maggiore","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.09.010_bib31","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2018.36.15_suppl.10009","article-title":"Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT)","volume":"36","author":"Celis","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.09.010_bib32","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2018-99-113087","article-title":"Patient treatment preferences for relapsed\/refractory multiple myeloma: are patients willing to trade off efficacy for tolerability?","volume":"132","author":"Auclair","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.09.010_bib33","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/blood-2018-99-112921","article-title":"Patient preferences for multiple myeloma (MM) treatment: interim analysis of a discrete choice experiment","volume":"132","author":"McKay","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.09.010_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:15Z","timestamp":1761870975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020305486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2152265020305486"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.09.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}